Program
MB11
A development code. Also written as “MB11 (Proposed Nivolumab Biosimilar)”.
Its studies are mostly in Neoplasm Metastasis, led by Fresenius Kabi.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Fresenius Kabi | 11 open or running | phase 3since Oct 6, 2025 | Oct 6, 2025 | Apr 2027phase 3 · NCT07221734 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 6, 2025First study: phase 3 study in Neoplasm MetastasisFirst studyNCT07221734 · 632 planned · Bosnia and Herzegovina, Brazil, Chile and more
Ahead
- Apr 2027Primary completion: phase 3 study in Neoplasm MetastasisNCT07221734
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07221734Neoplasm Metastasis · Bosnia and Herzegovina, Brazil, Chile and more | 3 | Recruiting | Apr 2027 | 632 |
How it is read
Names in the registry
- “MB11 (Proposed Nivolumab Biosimilar)”, 1 entry
Codes read as this program: MB11.
Conditions, from the studies’ own filings
- Neoplasm Metastasis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.